CD52 / DyLight 405 / Campath-1H
Product Details
| Description | Human CD52 antigen, also known as CAMPATH-1. CD52 is expressed at high density by lymphocytes, monocytes, eosinophils, thymocytes and macrophages. It is expressed by most lymphoid derived malignancies, although expression on myeloma cells is variable. | |
|---|---|---|
| Conjugate | DyLight 405 | |
| Clone | Campath-1H | |
| Target Species | Cynomolgus, Human, Rhesus | |
| Applications | ELISA, FC, IF, IHC-P, WB, IHC-Fr, IHC | |
| Supplier | Novus Biologicals | |
| Catalog # | Sign in to view product details, citations, and spectra | |
| Size | ||
| Price | ||
| Antigen | ||
| Host | ||
| Isotype |
About CD52
Involved in positive regulation of cytosolic calcium ion concentration. Predicted to be located in extracellular region and plasma membrane. Predicted to be intrinsic component of plasma membrane. Predicted to be active in sperm midpiece. [provided by Alliance of Genome Resources, Apr 2022]
Involved in positive regulation of cytosolic calcium ion concentration. Predicted to be located in extracellular region and plasma membrane. Predicted to be intrinsic component of plasma membrane. Predicted to be active in sperm midpiece. [provided by Alliance of Genome Resources, Apr 2022]
About DyLight 405
DyLight™ 405 has an excitation peak at 400 nm and an emission peak at 420 nm and is spectrally similar to Alexa Fluor™ 405 and Cascade Blue. DyLight™ 405 is most commonly used in flow cytometery and fluorescence microscopy applications.
DyLight™ 405 has an excitation peak at 400 nm and an emission peak at 420 nm and is spectrally similar to Alexa Fluor™ 405 and Cascade Blue. DyLight™ 405 is most commonly used in flow cytometery and fluorescence microscopy applications.
Experiment Design Tools
Panel Builders
Looking to design a Microscopy or Flow Cytometry experiment?
Validation References
| Additional Sources |
|
|---|
Reviews & Ratings
| Reviews |
|---|
Looking for more options?
644 CD52 antibodies from over 32 suppliers available with over 65 conjugates.
